Not Yet Recruiting PHASE1 INTERVENTIONAL 2-arm
NCT06800131
Hepatitis B Vaccine Delivered Trans-dermally by MAP
A Phase I, Randomized, Open-Label, Active-Control Study to Evaluate Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Delivered Trans-dermally by Microneedle Array Patch (MAP) in Healthy Adults
Sponsor: International Vaccine Institute
Conditions
Hepatitis B Vaccine
Interventions
Active comparator vaccine via intramuscular injection Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)
Updated 1 time since 2025 Last updated: Jan 24, 2025 Started: Feb 5, 2025 Primary completion: Aug 5, 2026 Completion: Nov 5, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1 clinical study on Hepatitis B Vaccine, this trial is actively recruiting participants. The trial is conducted by International Vaccine Institute and has accumulated 1 data snapshot since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- International Vaccine Institute
- QuadMedicine
Data source: International Vaccine Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.